Compare Tidewater Inc (TDW) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tidewater Inc vs BIO-TECHNE Corp — how do they compare? Tidewater Inc trades at $90.62 (market cap $4.46B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 2.5× Tidewater Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals.
| TDW | TECH | |
|---|---|---|
Market Cap | $4.46B | $11.24B |
Sector | Utilities | Health |
52-Week High | $91.12 | $72.29 |
52-Week Low | $47.29 | $43.31 |
Enterprise Value | $4.50B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tidewater (TDW) trades at $82.84, up 1.56% today, with a bullish technical signal from moving averages and strong support at $81. The company reported Q2 2026 EPS of $0.43, beating estimates, but has missed expectations in recent quarters. Revenue for 2025 was $1.35B with a net income margin of 18.34%, though 2026 projections show a decline to $1.3B and lower margins. Analyst consensus is mixed with 26.92% buy ratings, while institutional holdings saw increases from First Trust Advisors and Bank of New York Mellon in 2026.
Outlook: TDW benefits from operational strength and bullish technicals, but earnings misses and margin compression pose risks. Investors should weigh solid cash flow against competitive and macroeconomic headwinds in the oil and gas sector.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
